Andrade Robert 4
4 · FENNEC PHARMACEUTICALS INC. · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Fennec Pharmaceuticals CFO Robert Andrade Receives 1,558 Shares
What Happened
- Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals (FENC), was reported to have acquired 1,558 shares on January 31, 2026. The shares were recorded at $0.00 (no cash paid), reflecting the release of previously restricted shares rather than an open-market purchase.
Key Details
- Transaction date: 2026-01-31. Form 4 filed: 2026-02-02.
- Transaction type/code: A — Award/other acquisition; 1,558 shares @ $0.00 (acquired).
- Shares owned after the transaction: Not disclosed in this filing.
- Footnote: Shares were released from restrictions from awards dated 03/31/2023 and 05/16/2024.
- Timeliness: Form filed on Feb 2, 2026; no late filing indicator in the report.
Context
- This was a release of restricted shares from prior awards (compensation vesting), not an open-market purchase or sale. Such releases are common as time- or performance-based vesting conditions are met and do not by themselves signal insider buying or selling intent. Retail investors should watch future filings if the insider later sells or makes an open-market purchase.
Insider Transaction Report
Form 4
Andrade Robert
CHIEF FINANCIAL OFFICER
Transactions
- Award
Common shares
[F1]2026-01-31+1,558→ 212,658 total
Footnotes (1)
- [F1]Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024.
Signature
/s/ Robert Andrade|2026-02-02